The impact of the interval between the induction of chemotherapy and radiotherapy on the survival of patients with nasopharyngeal carcinoma
Authors Yang S, Fu X, Huang G, Chen J, Luo S, Wang Z, Kong F, Wu G, Lin S, Wang F, Chen L
Received 22 November 2018
Accepted for publication 29 January 2019
Published 22 March 2019 Volume 2019:11 Pages 2313—2320
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 3
Editor who approved publication: Dr Chien-Feng Li
Shiping Yang,1,2,* Xiaoling Fu,3,* Guang Huang,2 Junni Chen,2 Shishi Luo,4 Zhenping Wang,4 Fanzhong Kong,2 Gang Wu,2 Shaomin Lin,2 Fen Wang,2 Longhua Chen1
1Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China; 2Department of Radiation Oncology, Hainan General Hospital, Haikou, Hainan, China; 3Blood Transfusion Department, Maternal and Child Health Hospital of Hainan Province and Hainan Children’s Hospital, Haikou, Hainan, China; 4Department of Radiology, Hainan General Hospital, Haikou, Hainan, China
*These authors contributed equally to this work
Background: There have been no reliable scientific studies examining whether the interval between induction chemotherapy (IC) and initiating radiotherapy is associated with poor outcomes of nasopharyngeal carcinoma (NPC).
Patients and methods: In this retrospective study, we included a total of 239 local advanced NPC patients who underwent concurrent chemoradiotherapy and IC. Based on the interval between IC and intensity-modulated radiation therapy (IMRT), the patients were classified into three groups as follows: Group A (≤7 vs >7 days), Group B (≤14 vs >14 days), and Group C (≤ 21 vs >21 days). Univariate and multivariate regression analyses were performed to determine the prognostic factors of survival outcomes. The differences between the two groups were compared by the log-rank test.
Results: The median IC-IMRT interval was 9 days (range, 1–76 days). The median follow-up time was 40 months (range, 4–58 months). The IC-IMRT interval including Group A, Group B, and Group C was not significantly associated with overall survival (OS), distant metastasis-free survival (DMFS), locoregional relapse-free survival (LRFS), or disease-free survival (DFS). Multivariate analysis showed that the tumor stage was the independent significant predictor for OS, DMFS, LRFS, and DFS. But it appears that there was a trend toward improvement in the outcome of ≤7 days group in OS from the Kaplan–Meier curves.
Conclusion: It is also feasible to postpone radiotherapy for 1–3 weeks if patients were unable to receive treatment immediately due to chemotherapy complications such as bone marrow suppression. However, we suggest that patients should start IMRT as soon as possible after IC.
Keywords: nasopharyngeal carcinoma, interval, induction chemotherapy, radiotherapy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]